We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-13.46%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$627M
AUM Growth
-$205M
Cap. Flow
-$88.2M
Cap. Flow %
-14.06%
Top 10 Hldgs %
25.67%
Holding
102
New
6
Increased
38
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$15.4M
2
HUM icon
Humana
HUM
+$14.8M
3
PFE icon
Pfizer
PFE
+$14.2M
4
MCK icon
McKesson
MCK
+$11M
5
AMGN icon
Amgen
AMGN
+$10.4M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$18.6M
3
UNH icon
UnitedHealth
UNH
+$10.1M
4
RAD
Rite Aid Corporation
RAD
+$9.6M
5
CVS icon
CVS Health
CVS
+$9.15M

Sector Composition

Rank Sector Weight
1 Healthcare 91.99%
2 Financials 2.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
76
Xencor
XNCR
$1.56B
$2.22M 0.35%
181,303
-6,697
-4% -$131K
LXRX icon
77
Lexicon Pharmaceuticals
LXRX
$1.08B
$2.15M 0.34%
200,000
+29,085
+17% +$318K
CMRX
78
DELISTED
Chimerix, Inc.
CMRX
$2.14M 0.34%
56,000
-10,000
-15% -$494K
TSRO
79
DELISTED
TESARO, Inc.
TSRO
$2.04M 0.33%
50,899
– –
ACHN
80
DELISTED
Achillion Pharmaceuticals
ACHN
$1.94M 0.31%
280,000
– –
TNDM icon
81
Tandem Diabetes Care
TNDM
$1.59B
$1.84M 0.29%
20,900
– –
MRTX
82
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.72M 0.27%
50,000
– –
ARRY
83
DELISTED
Array Biopharma Inc
ARRY
$1.69M 0.27%
370,000
– –
TTPH
84
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.68M 0.27%
11,250
+5,880
+109% +$4.32M
ANTH
85
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.52M 0.24%
31,250
-46,200
-60% -$3.23M
DVAX
86
DELISTED
Dynavax Technologies
DVAX
$1.35M 0.22%
55,000
-67,835
-55% -$1.92M
RGLS
87
DELISTED
Regulus Therapeutics
RGLS
$1.31M 0.21%
+1,667
New +$1.71M
HOLX
88
DELISTED
Hologic
HOLX
$1.3M 0.21%
33,301
-59,699
-64% -$2.37M
ADVM
89
DELISTED
Adverum Biotechnologies
ADVM
$1.27M 0.2%
15,401
– –
MTEM
90
DELISTED
Molecular Templates, Inc.
MTEM
$820K 0.13%
1,221
– –
BIND
91
DELISTED
BIND THERAPEUTICS INC
BIND
$596K 0.1%
133,535
– –
BHC icon
92
Bausch Health
BHC
$2.4B
– –
-32,248
Closed -$7.16M
BIIB icon
93
Biogen
BIIB
$30.8B
– –
-50,291
Closed -$20.3M
JNJ icon
94
Johnson & Johnson
JNJ
$625B
– –
-191,000
Closed -$18.6M
OEF icon
95
PUT
iShares S&P 100 ETF
OEF
$20.5B
– –
-200,000
Closed -$73.8M
TEVA icon
96
Teva Pharmaceuticals
TEVA
$41.2B
– –
-92,000
Closed -$5.44M
TMO icon
97
Thermo Fisher Scientific
TMO
$220B
– –
-37,000
Closed -$4.8M
XLV icon
98
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.6B
– –
-700,000
Closed -$52.1M
EPZM
99
DELISTED
Epizyme, Inc
EPZM
– –
-131,785
Closed -$3.16M
AMSG
100
DELISTED
Amsurg Corp
AMSG
– –
-70,000
Closed -$4.9M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2015 Portfolio in Review

As of Q3 2015, Rhenman & Partners Asset Management held 102 positions worth $627M, down 25% from $833M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $88.2M in Q3 2015, closing 11 positions and reducing 34 holdings. Its most notable exit was Biogen, an estimated $20.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 77% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Cigna worth $14.3M.

  • Rhenman & Partners Asset Management's largest Q3 2015 buy was Cigna: 105,900 shares worth $14.3M.
  • Rhenman & Partners Asset Management added most to McKesson in Q3 2015, an estimated $11M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2015 reduction was UnitedHealth, cutting an estimated $10.1M.
  • Rhenman & Partners Asset Management fully exited Biogen in Q3 2015, selling an estimated $20.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $627M portfolio in Q3 2015.
  • Rhenman & Partners Asset Management opened 6 new positions and closed 11 in Q3 2015.
  • Rhenman & Partners Asset Management's portfolio value fell 25% quarter-over-quarter to $627M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2015, filed 26 Oct 2015.